MedTrace Logo

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

NCT00581425 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2013-01-25

No results posted yet for this study

Summary

A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.

Conditions

Interventions

BIOLOGICAL

Imiquimod and Interferon alpha

Imiquimod first two weeks and last two weeks. Interferon middle five weeks.

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Stephen B Tucker, M.D. · University of Texas Health Science Center of Houston Dermatology Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00581425 on ClinicalTrials.gov